StemCells, Inc. to Participate at the 17th Annual BIO CEO & Investor Conference
February 02 2015 - 8:00AM
StemCells, Inc. (Nasdaq:STEM) announced today that Management will
make a presentation on the Company's programs and operations at the
17th Annual BIO CEO & Investor Conference. Management is
scheduled to speak at 8:30 a.m. EST on Monday, February 9, at the
Waldorf Astoria in New York City.
A live webcast of the presentations will be available through
the Company's corporate website http://www.stemcellsinc.com.
Interested parties are encouraged to connect to the website at
least 15 minutes prior to the presentation to ensure adequate time
for any software downloads that may be necessary. In addition, you
may directly access the webcast through the following link
http://www.veracast.com/webcasts/bio/ceoinvestor2015/67102124699.cfm.
A replay will also be accessible for 90 days through the Company's
website.
About StemCells, Inc.
StemCells, Inc. is currently engaged in clinical development of
its HuCNS-SC (purified human neural stem cells) platform
technology, as a potential treatment for diseases and disorders of
the central nervous system. Interim data from the Company's Phase
I/II clinical trial in thoracic spinal cord injury shows measurable
gains involving multiple sensory modalities and segments in half of
the subjects, two of whom converted from complete injury (AIS A) to
incomplete injury (AIS B), post-transplant. Enrollment has recently
commenced in the Company's Phase II clinical trial in cervical SCI.
StemCells, Inc. has also completed enrollment and treatment in its
Phase I/II clinical trial in geographic atrophy of age-related
macular degeneration (GA-AMD), the most severe form of dry AMD,
which is the leading cause of blindness in the elderly. Interim
results for those subjects with 12 month follow-up post
transplantation of HuCNS-SC cells into the eye, show a reduction in
the rate of disease progression as compared to the control
(untreated) eye and to the expected natural history of the disease.
In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD),
a fatal myelination disorder in children, the Company showed
preliminary evidence of progressive and durable donor-derived
myelination in all four patients transplanted with HuCNS-SC cells.
Further information about StemCells, Inc. is available at
http://www.stemcellsinc.com.
Apart from statements of historical fact, the text of this press
release constitutes forward-looking statements within the meaning
of the U.S. securities laws, and is subject to the safe harbors
created therein. These forward-looking statements speak only as of
the date of this news release. The Company does not undertake to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof. Such statements
reflect management's current views and are based on certain
assumptions that may or may not ultimately prove valid. The
Company's actual results may vary materially from those
contemplated in such forward-looking statements due to risks and
uncertainties to which the Company is subject, including those
described under the heading "Risk Factors" in the Company's Annual
Report on Form 10-K for the year ended December 31, 2013 and in its
subsequent reports on Forms 10-Q and 8-K.
CONTACT: Greg Schiffman
StemCells, Inc.
Chief Financial Officer
(510) 456-4128
Andrea Flynn
Russo Partners
(646) 942-5631
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Sep 2023 to Sep 2024